Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +42.04%
#3 Pons Pons +20.06%
#4 Main Street Yield Main Street Yield +17.48%
#5 龙虾 (Lobster) 龙虾 (Lobster) +16.94%
#6 o1.exchange o1.exchange +14.33%
#7 Ontology Gas Ontology Gas +13.66%
#8 Collect on Fanable Collect on Fanable +13.51%
#9 OpenGradient OpenGradient +11.97%
#10 Velvet Velvet +11.60%
Coin of the day
GEKKO GEKKO
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Rangering i aksjer #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Aksjekurs
$14.07
Sist synkronisert: 2026-08-28
Markedsverdi
$1.18B
Endring (1 dag)
-4.41%
Endring (1 år)
145.13%
Land
US
Handel Corvus Pharmaceuticals, Inc. (CRVS)

Kategori

Healthcare
Utbyttehistorikk for Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (aksjesymbol: CRVS) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Corvus Pharmaceuticals, Inc. (CRVS) fra 2026 til 2026
Årlige utbyttebetalinger
År Utbytte (justert for aksjesplitt) Endre
Ikke nok data for de angitte datoene.
Liste over alle utbyttebetalinger
År Utbytte Endre
Ikke nok data for de angitte datoene.
Utbyttebetalinger for lignende selskaper eller konkurrenter
Selskap Antall utbyttebetalinger Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH